Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 19:14:1292416.
doi: 10.3389/fphar.2023.1292416. eCollection 2023.

Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity

Stefan Stewart  1 , Jose Manuel Dodero-Anillo  2 , Javier Guijarro-Eguinoa  1 , Pedro Arias  3 , Arturo Gómez López De Las Huertas  1 , Enrique Seco-Meseguer  1 , Irene García-García  1 , Elena Ramírez García  1   4 , Carlos Rodríguez-Antolín  5 , Antonio J Carcas  1   4 , Sonia Rodriguez-Novoa  6 , Rocio Rosas-Alonso  3   5 , Alberto M Borobia  1   4
Affiliations

Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity

Stefan Stewart et al. Front Pharmacol. .

Abstract

The field of pharmacogenetics (PGx) holds great promise in advancing personalized medicine by adapting treatments based on individual genetic profiles. Despite its benefits, there are still economic, ethical and institutional barriers that hinder its implementation in our healthcare environment. A retrospective analysis approach of anonymized data sourced from electronic health records was performed, encompassing a diverse patient population and evaluating key parameters such as prescribing patterns and test results, to assess the impact of pharmacogenetic testing. A head-to-head comparison with previously published activity results within the same pharmacogenetic laboratory was also conducted to contrast the progress made after 10 years. The analysis revealed significant utilization of pharmacogenetic testing in daily clinical practice, with 1,145 pharmacogenetic tests performed over a 1-year period and showing a 35% growth rate increase over time. Of the 17 different medical departments that sought PGx tests, the Oncology department accounted for the highest number, representing 58.47% of all genotyped patients. A total of 1,000 PGx tests were requested for individuals susceptible to receive a dose modification based on genotype, and 76 individuals received a genotype-guided dose adjustment. This study presents a comprehensive descriptive analysis of real-world data obtained from a public tertiary hospital laboratory specialized in pharmacogenetic testing, and presents data that strongly endorse the integration of pharmacogenetic testing into everyday clinical practice.

Keywords: personalized medicine; pharmacogenetic dosing; preemptive genotyping; real-world data; retrospective analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Overall functioning of the Clinical Pharmacogenetics Unit for drugs for which the PGx testing is required before treatment prescription (preemptive genotyping in high-risk populations). (B) Overall functioning of the Clinical Pharmacogenetics Unit when a medical case is referred where a PGx test could be deemed appropriate or a request is made for a drug without established clinical protocols.
FIGURE 2
FIGURE 2
(A) Percentage (%) of analyzed genes in total sample. (B) Percentage (%) of analyzed genes in total sample.
FIGURE 3
FIGURE 3
(A) Total number of pharmacogenetic tests performed in the study period. Number of tests requests requested for patients susceptible to treatment adjustment. Number of genotypes that led to treatment adjustment stratified by genes. (B) Percentage (%) of pharmacogenetic test results per gene that warranted a phenotype-based treatment adjustment.
See this image and copyright information in PMC

References

    1. Agencia Española del Medicamento y Productos Sanitarios (AEMPS) (2020). Security Alert: fluorouracil, capecitabine, tegafur, and flucytosine in patients with dihydropyrimidine dehydrogenase deficiency. Available at: https://www.aemps.gob.es/informa-en/fluorouracilo-capecitabina-tegafur-y... (Accessed June 16, 2023).
    1. Bielinski S. J., Olson J. E., Pathak J., Weinshilboum R. M., Wang L., Lyke K. J., et al. (2014). Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin. Proc. 89, 25–33. 10.1016/J.MAYOCP.2013.10.021 - DOI - PMC - PubMed
    1. Bignucolo A., De Mattia E., Roncato R., Peruzzi E., Scarabel L., D’Andrea M., et al. (2023). Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: lessons learned on the path to implementation. Front. Pharmacol. 14, 1199462. 10.3389/fphar.2023.1199462 - DOI - PMC - PubMed
    1. Birdwell K. A., Decker B., Barbarino J. M., Peterson J. F., Stein C. M., Sadee W., et al. (2015). Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin. Pharmacol. Ther. 98, 19–24. 10.1002/cpt.113 - DOI - PMC - PubMed
    1. Borobia A. M., Dapia I., Tong H. Y., Arias P., Muñoz M., Tenorio J., et al. (2018). Clinical implementation of pharmacogenetic testing in a hospital of the Spanish national health system: strategy and experience over 3 years. Clin. Transl. Sci. 11, 189–199. 10.1111/cts.12526 - DOI - PMC - PubMed

LinkOut - more resources